Clinical trials: Pulmonary Infection
Sepsis, Pneumonia
Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia
An adaptive platform trial to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or lower respiratory tract infection.
- Conditions
- Sepsis, Pneumonia, Lower Resp Tract Infection, Covid19
- Trial name
- ACCOMPLISH (NCT04829188)
- Testing
- Structured Telephone Support (STS), Low-intensity Remote Patient Monitoring (RPM-Low), High-intensity Remote Patient Monitoring (RPM-High)
- Where
- United States
- Volunteers
- 1,296 people
- Sponsor
- University of Pittsburgh
COVID-19
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
- Trial name
- NCT04354831
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Medical College of Wisconsin
Pulmonary Disease, COPD
Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate a multifaceted intervention to improve the quality of end-of-life communication between patients with COPD and their primary care providers using information about patients preferences for…
- Conditions
- Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00106080
- Testing
- Audit and Feedback
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- VA Office of Research and Development
COVID
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
This is a phase 1b randomized, double-blind, placebo-controlled study in adult subjects with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04397796
- Testing
- BM-Allo.MSC
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
COVID-19
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
- Trial name
- NCT04784897
- Testing
- Brilacidin, Standard of Care (SoC)
- Where
- 12 sites in United States, Russia
- Volunteers
- 120 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
- Trial name
- iBEST-1 (NCT02712983)
- Testing
- TIP
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent…
- Trial name
- NCT06568861
- Testing
- ALG-097558
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Pneumonia
Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
The purpose of this study is to compare the efficacy and safety of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).
- Trial name
- NCT00336544
- Testing
- Cethromycin, Clarithromycin
- Where
- 13 sites in United States
- Volunteers
- 522 people
- Sponsor
- Advanced Life Sciences, Inc.
Covid19
Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19
This is a single-center, randomized double blind placebo controlled trial to evaluate the efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized with severe COVID-19 at Northwestern Memorial…
- Trial name
- NCT04634799
- Testing
- TM5614
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
COVID-19
Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated…
- Trial name
- COVID-Lambda (NCT04331899)
- Testing
- Peginterferon Lambda-1a
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
COVID-19 Vaccines, Telemedicine
Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool
This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19).
- Conditions
- COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
- Trial name
- MoVeUP (NCT05386355)
- Testing
- COVID-19 Vaccine Uptake App, General Health App
- Where
- 15 sites in United States
- Volunteers
- 1,934 people, healthy volunteers welcome
- Sponsor
- IDeA States Pediatric Clinical Trials Network
COVID-19 Respiratory Infection, Aspergillosis
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients.
- Trial name
- POSACOVID (NCT05065658)
- Testing
- Posaconazole
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 249 people
- Sponsor
- Medical University of Graz
Tuberculosis, Pulmonary
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups. H56:IC31 (investigational vaccine) Placebo 900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are…
- Trial name
- NCT03512249
- Testing
- H56:IC31
- Where
- 6 sites in South Africa, Tanzania
- Volunteers
- 831 people
- Sponsor
- International AIDS Vaccine Initiative
COVID-19
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication.
- Trial name
- NCT05605093
- Testing
- Shionogi Protease Inhibitor (S-217622)
- Where
- 187 sites in United States, Argentina and 22 more
- Volunteers
- 602 people
- Sponsor
- University of Minnesota
Pulmonary Tuberculosis
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of PA-824 at 50, 100, 150 and 200 mg per day in adult patients with newly diagnosed, uncomplicated, smear positive…
- Trial name
- NCT00944021
- Testing
- PA-824, Rifafour e-275 mg
- Volunteers
- 69 people
- Sponsor
- Global Alliance for TB Drug Development
Sepsis, Acute Lung Injury
Statins for Acutely Injured Lungs From Sepsis
Objective: assess the efficacy and safety of oral rosuvastatin in patients with sepsis-induced Acute Lung Injury (ALI). Hypothesis: Rosuvastatin therapy will improve mortality in patients with sepsis-induced ALI.
- Trial name
- SAILS (NCT00979121)
- Testing
- Rosuvastatin
- Where
- 40 sites in United States
- Volunteers
- 745 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against…
- Trial name
- NCT04588480
- Testing
- BNT162b2
- Where
- 2 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19
Test to Stay in School: COVID-19 Testing Following Exposure in School Communities
Participants in school communities who have been exposed to SARS-CoV-2 will be tested for COVID-19 on the day of exposure (day 1) and at days 3, 5, and 7 following initial known exposure.
- Trial name
- NCT05052580
- Testing
- COVID-19 Testing
- Where
- United States
- Volunteers
- 4,733 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.